Drug combo for advanced ampullary cancer
Part of Cancer clinical trials.
This trial tests a combination of three drugs (Surufatinib, Toripalimab, and chemotherapy) as a first treatment for ampullary cancer that cannot be removed by surgery or has come back after earlier treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have ampullary cancer that has spread or cannot be removed by surgery, and it has not been treated with systemic therapy before.
- You are in generally good health (able to do daily activities without much help).
- You have at least one tumor that can be measured on scans.
- Your blood counts and liver/kidney function are within acceptable ranges.
- You are willing to use effective birth control during the study.
- You have not had certain other cancer drugs before (like certain targeted therapies or immunotherapies).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (surufatinib and toripalimab) plus a chemotherapy infusion directly into the liver artery (HAIC) for people with bile duct cancer that cannot be removed by surgery or has spread. The goal is to see if this combination can shrink tumors or slow the cancer.
This trial tests a combination of surufatinib (a targeted drug) plus immunotherapy and chemotherapy for people with bile duct or gallbladder cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink tumors or slow the cancer's growth.
This trial tests if adding two targeted drugs (surufatinib and serplulimab) to standard chemotherapy can shrink locally advanced pancreatic cancer enough to allow surgery. It may help people whose cancer hasn't spread and who haven't had prior treatment.
This trial tests a combination of three drugs—surufatinib, chemotherapy (mFOLFIRINOX), and an immunotherapy (PD-1 inhibitor)—given before surgery to shrink tumors and improve outcomes for people with pancreatic cancer that is high-risk or borderline resectable.
This trial tests a combination of four drugs (surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine) as a first treatment for people whose pancreatic cancer has spread to other parts of the body. The goal is to see if this combination helps shrink tumors and improve survival.
This trial studies whether a combination of surufatinib and immunotherapy (camrelizumab, plus an “AS” medicine) can slow or shrink advanced pancreatic cancer that has spread. It is for people starting treatment for advanced disease for the first time and may help those who have measurable tumors and meet safety test limits.
Hear when a new Ampullary Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.